TAIHO PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 1963-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.taiho.co.jp
Clinical Trials
283
Active:11
Completed:119
Trial Phases
4 Phases
Phase 1:66
Phase 2:75
Phase 3:83
+1 more phases
Drug Approvals
15
NMPA:10
FDA:3
PHILIPPINES:2
Drug Approvals
Trifluridine and Tipiracil Hydrochloride Tablets
- Product Name
- 曲氟尿苷替匹嘧啶片
- Approval Number
- 国药准字HJ20190048
- Approval Date
- Aug 6, 2024
NMPA
Trifluridine and Tipiracil Hydrochloride Tablets
- Product Name
- 曲氟尿苷替匹嘧啶片
- Approval Number
- 国药准字HJ20190049
- Approval Date
- Aug 6, 2024
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- 国药准字HJ20130817
- Approval Date
- Aug 24, 2023
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- 国药准字HJ20130816
- Approval Date
- Aug 24, 2023
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- 国药准字HJ20130812
- Approval Date
- Aug 24, 2023
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- 国药准字HJ20130811
- Approval Date
- Aug 24, 2023
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- H20130811
- Approval Date
- Oct 17, 2018
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- H20130817
- Approval Date
- Oct 17, 2018
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- H20130816
- Approval Date
- Oct 17, 2018
NMPA
Tegafur Gimeracil Oteracil Potassium Capsule
- Product Name
- 爱斯万
- Approval Number
- H20130812
- Approval Date
- Oct 17, 2018
NMPA
Clinical Trials
Distribution across different clinical trial phases (249 trials with phase data)• Click on a phase to view related trials
Phase 3
83 (33.3%)Phase 2
75 (30.1%)Phase 1
66 (26.5%)Not Applicable
18 (7.2%)phase_1_2
5 (2.0%)phase_2_3
2 (0.8%)A Study of TAS3731 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Adult Males
- Interventions
- Drug: TAS3731 Dose1Drug: TAS3731 Dose2Drug: TAS3731 Dose3Drug: Placebo
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 238
- Registration Number
- NCT05691660
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: TAS-303, [14C]TAS-303
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05621447
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
Phase 2
Completed
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: TAS5315 Dose 2Drug: PlaceboDrug: TAS5315 Dose 1Drug: TAS5315 Dose 3Drug: TAS5315 Dose 4Drug: TAS5315 Dose 5
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT05335499
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Yokohama, Japan
A Study of Pimitespib in Combination with Imatinib in Patients with GIST (CHAPTER-GIST-101)
Phase 1
Recruiting
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05245968
- Locations
- 🇦🇺
Flinders Medical Center, Adelaide, Australia
🇦🇺Alfred Health, Melbourne, Australia
🇨🇳Beijing Cancer Hospital, Beijing, China
AB122 Platform Study
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid TumorPancreatic Ductal AdenocarcinomaColorectal CancerNon-small Cell Lung CancerGastric CancerAlveolar Soft Part SarcomaEsophageal CancerHead and Neck CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found